TRANSPLANTATION AND CELLULAR ENGINEERING
Female donors and donors who are lighter than their recipient are less likely to meet the CD34+ cell dose requested for peripheral blood stem cell transplantation
Annelies Billen,
J. Alejandro Madrigal,
Richard M. Szydlo, Bronwen E. Shaw,
Corresponding Author
Annelies Billen
UCL Cancer Institute, London, UK
Anthony Nolan, London, UK
Address reprint requests to: Annelies Billen, Anthony Nolan, 2 Heathgate Place, 75-87 Agincourt Road, London NW3 2NU, UK; e-mail: [email protected].Search for more papers by this authorJ. Alejandro Madrigal
UCL Cancer Institute, London, UK
Anthony Nolan, London, UK
Search for more papers by this authorBronwen E. Shaw
UCL Cancer Institute, London, UK
Anthony Nolan, London, UK
Royal Marsden Hospital, London, UK
Search for more papers by this authorAnnelies Billen,
J. Alejandro Madrigal,
Richard M. Szydlo, Bronwen E. Shaw,
Corresponding Author
Annelies Billen
UCL Cancer Institute, London, UK
Anthony Nolan, London, UK
Address reprint requests to: Annelies Billen, Anthony Nolan, 2 Heathgate Place, 75-87 Agincourt Road, London NW3 2NU, UK; e-mail: [email protected].Search for more papers by this authorJ. Alejandro Madrigal
UCL Cancer Institute, London, UK
Anthony Nolan, London, UK
Search for more papers by this authorBronwen E. Shaw
UCL Cancer Institute, London, UK
Anthony Nolan, London, UK
Royal Marsden Hospital, London, UK
Search for more papers by this authorAbstract
Background
It is of clinical relevance to recognize donors who are unlikely to meet the requested stem cell dose for transplantation, as this group may benefit from an alternative mobilization regimen. This study was performed to evaluate the frequency of unrelated donor peripheral blood stem cell (PBSC) collections that meet the target yield and the impact of donor factors on this.
Study Design and Methods
All sequential PBSC collections facilitated by the national registry (n = 323) from January through December 2011 were analyzed. Donor factors analyzed included age, sex, weight, and presence of a central line.
Results
In univariate analyses, we found that reaching the target yield was significantly associated with a higher donor weight (85.6 kg vs. 75.3 kg, p < 0.001), male donor sex (55% vs. 19%, p < 0.001), a positive difference in weight between donor and recipient (4.3 kg vs. −8 kg, p < 0.001), and a higher volume of blood processed (13.8 L vs. 11.9 L, p < 0.001). After stepwise binary logistic regression, sex (p < 0.001) and difference between donor and recipient weight (p < 0.005) remained significantly associated with target yield being met after 1 day of collection.
Conclusions
This study shows than women and donors who are lighter than their recipient have a decreased likelihood of meeting the transplant physician's requested dose. New strategies to improve mobilization in such donors are needed. These findings may also impact future donor recruitment strategies.
References
- 1 Mavroudis D, Read E, Cottler-Fox M, et al. CD34+ cell dose predicts survival, posttransplant morbidity, and rate of hematologic recovery after allogeneic marrow transplants for hematologic malignancies. Blood 1996; 88: 3223-3229.
- 2 Shpall EJ, Champlin R, Glaspy JA. Effect of CD34+ peripheral blood progenitor cell dose on hematopoietic recovery. Biol Blood Marrow Transplant 1998; 4: 84-92.
- 3 Mehta J, Mehta J, Frankfurt O, et al. Optimizing the CD34 + cell dose for reduced-intensity allogeneic hematopoietic stem cell transplantation. Leuk Lymphoma 2009; 50: 1434-1441.
- 4 Pulsipher MA, Chitphakdithai P, Logan BR, et al. Donor, recipient, and transplant characteristics as risk factors after unrelated donor PBSC transplantation: beneficial effects of higher CD34+ cell dose. Blood 2009; 114: 2606-2616.
- 5 Heimfeld S. HLA-identical stem cell transplantation: is there an optimal CD34 cell dose? Bone Marrow Transplant 2003; 31: 839-845.
- 6 Nakamura R, Auayporn N, Smith DD, et al. Impact of graft cell dose on transplant outcomes following unrelated donor allogeneic peripheral blood stem cell transplantation: higher CD34+ cell doses are associated with decreased relapse rates. Biol Blood Marrow Transplant 2008; 14: 449-457.
- 7 Przepiorka D, Smith TL, Folloder J, et al. Risk factors for acute graft-versus-host disease after allogeneic blood stem cell transplantation. Blood 1999; 94: 1465-1470.
- 8 Przepiorka D, Anderlini P, Saliba R, et al. Chronic graft-versus-host disease after allogeneic blood stem cell transplantation. Blood 2001; 98: 1695-1700.
- 9 Zaucha JM, Gooley T, Bensinger WI, et al. CD34 cell dose in granulocyte colony-stimulating factor-mobilized peripheral blood mononuclear cell grafts affects engraftment kinetics and development of extensive chronic graft-versus-host disease after human leukocyte antigen-identical sibling transplantation. Blood 2001; 98: 3221-3227.
- 10 Holig K, Kramer M, Kroschinsky F, et al. Safety and efficacy of hematopoietic stem cell collection from mobilized peripheral blood in unrelated volunteers: 12 years of single-center experience in 3928 donors. Blood 2009; 114: 3757-3763.
- 11 Pulsipher MA, Chitphakdithai P, Logan BR, et al. Acute toxicities of unrelated bone marrow versus peripheral blood stem cell donation: results of a prospective trial from the National Marrow Donor Program. Blood 2013; 121: 197-206.
- 12 Pulsipher M. Increased risk of severe adverse events after BM vs PBSC donation: results of a prospective study of 9494 NMDP donors (2004-2009). 2012 [cited 2014 Jan 1]. Available from: http://www.worldmarrow.org/fileadmin/Meeting/IDRC_Presentations/2012-IDRC-Sydney/20120504-Pulsipher.pdf
- 13 Stroncek DF, Clay ME, Jaszcz W, et al. Collection of two peripheral blood stem cell concentrates from healthy donors. Transfus Med 1999; 9: 37-50.
- 14 WMDA MWG. Minimum criteria needed for a specific donor to be available to a specific patient. 2010 [cited 2014 Jan 1]. Available from: http://www.worldmarrow.org/fileadmin/Committees/CLWG/DOC/20100101-CLWG-PPR-Cell_Dose.pdf
- 15 WMDA MWG. Summary of the responses to the “cell dose survey.” 2009 [cited 2014 Jan 1]. Available from: http://www.worldmarrow.org/fileadmin/Committees/CLWG/DOC/20100101-CLWG-SURV-Cell_Dose.pdf
- 16 Barnett D, Janossy G, Lubenko A, et al. Guideline for the flow cytometric enumeration of CD34+ haematopoietic stem cells. Prepared by the CD34+ haematopoietic stem cell working party. General Haematology Task Force of the British Committee for Standards in Haematology. Clin Lab Haematol 1999; 21: 301-308.
- 17 Ings SJ, Balsa C, Leverett D, et al. Peripheral blood stem cell yield in 400 normal donors mobilised with granulocyte colony-stimulating factor (G-CSF): impact of age, sex, donor weight and type of G-CSF used. Br J Haematol 2006; 134: 517-525.
- 18 Shimizu N, Asai T, Hashimoto S, et al. Mobilization factors of peripheral blood stem cells in healthy donors. Ther Apher 2002; 6: 413-418.
- 19 Martino M, Callea I, Condemi A, et al. Predictive factors that affect the mobilization of CD34(+) cells in healthy donors treated with recombinant granulocyte colony-stimulating factor (G-CSF). J Clin Apher 2006; 21: 169-175.
- 20 Anderlini P, Przepiorka D, Seong C, et al. Factors affecting mobilization of CD34+ cells in normal donors treated with filgrastim. Transfusion 1997; 37: 507-512.
- 21 Fischer JC, Frick M, Wassmuth R, et al. Superior mobilisation of haematopoietic progenitor cells with glycosylated G-CSF in male but not female unrelated stem cell donors. Br J Haematol 2005; 130: 740-746.
- 22 Vasu S, Leitman SF, Tisdale JF, et al. Donor demographic and laboratory predictors of allogeneic peripheral blood stem cell mobilization in an ethnically diverse population. Blood 2008; 112: 2092-2100.
- 23 Miflin G, Charley C, Stainer C, et al. Stem cell mobilization in normal donors for allogeneic transplantation: analysis of safety and factors affecting efficacy. Br J Haematol 1996; 95: 345-348.
- 24 Lysak D, Koza V, Jindra P. Factors affecting PBSC mobilization and collection in healthy donors. Transfus Apher Sci 2005; 33: 275-283.
- 25 Sohn SK, Kim JG, Chae YS, et al. Large-volume leukapheresis using femoral venous access for harvesting peripheral blood stem cells with the Fenwal CS 3000 Plus from normal healthy donors: predictors of CD34+ cell yield and collection efficiency. J Clin Apher 2003; 18: 10-15.
- 26 Lopez-Holgado N, Pata C, Villaron E, et al. Long-term bone marrow culture data are the most powerful predictor of peripheral blood progenitor cell mobilization in healthy donors. Haematologica 2005; 90: 353-359.
- 27 Suzuya H, Watanabe T, Nakagawa R, et al. Factors associated with granulocyte colony-stimulating factor-induced peripheral blood stem cell yield in healthy donors. Vox Sang 2005; 89: 229-235.
- 28 Pulsipher MA, Chitphakdithai P, Miller JP, et al. Adverse events among 2408 unrelated donors of peripheral blood stem cells: results of a prospective trial from the National Marrow Donor Program. Blood 2009; 113: 3604-3611.
- 29 Chen SH, Yang SH, Chu SC, et al. The role of donor characteristics and post-granulocyte colony-stimulating factor white blood cell counts in predicting the adverse events and yields of stem cell mobilization. Int J Hematol 2011; 93: 652-659.
- 30 Passos-Coelho JL, Machado MA, Lucio P, et al. Large-volume leukaphereses may be more efficient than standard-volume leukaphereses for collection of peripheral blood progenitor cells. J Hematother 1997; 6: 465-474.
- 31 Diaz MA, Sevilla J, de la Rubia J, et al. Factors predicting peripheral blood progenitor cell collection from pediatric donors for allogeneic transplantation. Haematologica 2003; 88: 919-922.
- 32 Bojanic I, Dubravcic K, Batinic D, et al. Large volume leukapheresis: efficacy and safety of processing patient's total blood volume six times. Transfus Apher Sci 2011; 44: 139-147.
- 33 Demirer T, Dagli M, Ilhan O, et al. A randomized trial of assessment of efficacy of leukapheresis volumes, 8 liters vs 12 liters. Bone Marrow Transplant 2002; 29: 893-897.
- 34 Schwarer AP, Messino NM, Gibson M, et al. A randomized trial of leukapheresis volumes, 7 L versus 10 L: an assessment of efficacy and patient tolerance. J Hematother Stem Cell Res 2000; 9: 269-274.
- 35 Kroger N, Zeller W, Hassan HT, et al. Stem cell mobilization with G-CSF alone in breast cancer patients: higher progenitor cell yield by delivering divided doses (2 × 5 microg/kg) compared to a single dose (1 × 10 microg/kg). Bone Marrow Transplant 1999; 23: 125-129.
- 36 Arbona C, Prosper F, Benet I, et al. Comparison between once a day vs twice a day G-CSF for mobilization of peripheral blood progenitor cells (PBPC) in normal donors for allogeneic PBPC transplantation. Bone Marrow Transplant 1998; 22: 39-45.
- 37 Kroger N, Renges H, Kruger W, et al. A randomized comparison of once versus twice daily recombinant human granulocyte colony-stimulating factor (filgrastim) for stem cell mobilization in healthy donors for allogeneic transplantation. Br J Haematol 2000; 111: 761-765.
- 38 de la Rubia J, Arbona C, de Arriba F, et al. Analysis of factors associated with low peripheral blood progenitor cell collection in normal donors. Transfusion 2002; 42: 4-9.
- 39 Devine SM, Vij R, Rettig M, et al. Rapid mobilization of functional donor hematopoietic cells without G-CSF using AMD3100, an antagonist of the CXCR4/SDF-1 interaction. Blood 2008; 112: 990-998.
- 40 Leotta S, Poidomani M, Mauro E, et al. AMD3100 for urgent PBSC mobilization and allogeneic transplantation from a normal donor after failed marrow harvest. Bone Marrow Transplant 2011; 46: 314-316.
- 41 Hauge AW, Haastrup EK, Sengelov H, et al. Addition of plerixafor for CD34+ cell mobilization in six healthy stem cell donors ensured satisfactory grafts for transplantation. Transfusion 2014; 54: 1055-1058.
- 42 Neumann T, Kruger WH, Busemann C, et al. Successful mobilization of PBSCs in a healthy volunteer donor by addition of plerixafor after failure of mobilization with G-CSF alone. Bone Marrow Transplant 2011; 46: 762-763.
- 43 Schriber J, Fauble V, Sproat LO, et al. Plerixafor “just in time” for stem cell mobilization in a normal donor. Bone Marrow Transplant 2011; 46: 1026-1027.
- 44 Juarez JG, Harun N, Thien M, et al. Sphingosine-1-phosphate facilitates trafficking of hematopoietic stem cells and their mobilization by CXCR4 antagonists in mice. Blood 2012; 119: 707-716.
Citing Literature
